Yousif Capital Management LLC Increases Stock Position in Protagonist Therapeutics, Inc. $PTGX

Yousif Capital Management LLC lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 4.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,404 shares of the company’s stock after buying an additional 1,067 shares during the quarter. Yousif Capital Management LLC’s holdings in Protagonist Therapeutics were worth $1,294,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. GF Fund Management CO. LTD. lifted its stake in shares of Protagonist Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company’s stock valued at $74,000 after buying an additional 275 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Protagonist Therapeutics by 4.1% in the 1st quarter. Hsbc Holdings PLC now owns 8,458 shares of the company’s stock worth $405,000 after purchasing an additional 330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Protagonist Therapeutics by 16.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company’s stock worth $132,000 after purchasing an additional 340 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Protagonist Therapeutics by 0.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after purchasing an additional 348 shares in the last quarter. Finally, CWM LLC lifted its stake in Protagonist Therapeutics by 201.5% in the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after purchasing an additional 407 shares in the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on PTGX shares. BMO Capital Markets reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday, October 13th. Leerink Partners started coverage on shares of Protagonist Therapeutics in a research note on Friday, September 12th. They issued an “outperform” rating and a $73.00 target price on the stock. JMP Securities increased their target price on shares of Protagonist Therapeutics from $67.00 to $69.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 7th. Johnson Rice set a $112.00 target price on shares of Protagonist Therapeutics in a research note on Monday, October 13th. Finally, Citigroup increased their target price on shares of Protagonist Therapeutics from $72.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $74.00.

Insider Buying and Selling at Protagonist Therapeutics

In related news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction on Friday, October 10th. The shares were sold at an average price of $81.62, for a total value of $979,440.00. Following the transaction, the director owned 5,130 shares in the company, valued at $418,710.60. This trade represents a 70.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 10,415 shares of Protagonist Therapeutics stock in a transaction on Friday, July 25th. The stock was sold at an average price of $54.78, for a total transaction of $570,533.70. Following the completion of the transaction, the chief executive officer owned 520,603 shares in the company, valued at approximately $28,518,632.34. The trade was a 1.96% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,935 shares of company stock worth $3,003,895. Corporate insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics stock opened at $76.72 on Tuesday. The firm’s fifty day moving average price is $63.00 and its 200-day moving average price is $54.36. The stock has a market cap of $4.77 billion, a P/E ratio of 109.60 and a beta of 2.20. Protagonist Therapeutics, Inc. has a fifty-two week low of $33.31 and a fifty-two week high of $93.25.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). The company had revenue of $5.55 million for the quarter, compared to analysts’ expectations of $8.32 million. Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. On average, analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.